Is Aspergillus nidulans susceptible to all antifungal agents? In vitro activity of an updated panel of antifungal agents against 63 clinical isolates

Peláez T., Guinea J., Gama B., Flores R., Recio S., Torres-Narbona M., Muñoz P., Bouza E.

Author address: 

NULL

Abstract: 

Background: Aspergillus nidulans is an infrequent but potential cause of invasive aspergillosis. However, its in vitro antifungal susceptibility profile has been poorly evaluated. We studied the antifungal susceptibility of an updated panel of 8 antifungal drugs against 63 clinical strains of A. nidulans collected in our hospital since 1997. Methods: The strains were from respiratory samples (n=55), superficial samples (n=5), and other samples (n=3) and were identified according to morphological characteristics. Antifungal susceptibility to amphotericin B, terbinafine, caspofungin, micafungin, itraconazole, voriconazole, posaconazole and isavuconazole was obtained following the CLSI M38-A procedure and the results analyzed using the t test and Pearson correlation coefficient (PC). Results: The antifungal susceptibility (MIC50, MIC90, geometric mean and ranges, in µg/mL) was as follows: amphotericin B (4/4/3.3/1-8), terbinafine (0.062/0.125/0.09/0.031-1), caspofungin (0.125/0.25/0.38/0.062-8), micafungin (0.062/0.062/0.065/0.062-0.125), itraconazole (1/2/1.036/0.25-4), voriconazole (0.5/2/0.61/0.062-2), posaconazole (0.5/1/0.54/0.25-1) and isavuconazole (0.25/1/0.46/0.062-1). Amphotericin B showed the lowest activity (52.3% of strains with MICs >= 4µg/mL) (P= 2 µg/mL) (P
2009

abstract No: 

P 1297

Full conference title: 

19th European Congress of Clinical Microbiology and Infectious Diseases
    • ECCMID 19th (2009)